Cancer genetics/epigenetics and the X chromosome: Possible new links for malignant glioma pathogenesis and immune-based therapies

Critical Reviews in Oncogenesis

Volumn 11, Issue 1, 2000, Pages 77-95

  Mintz, Akiva ^a   Debinski, Waldemar ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Chromosome X; DNA methylation; Epigenetics; Genetics; High grade gliomas; Immunotherapy; Receptors; SEREX; Tumor antigens; Vaccines

Indexed keywords

CANCER VACCINE; CYTOKINE RECEPTOR; INTERLEUKIN 13 RECEPTOR; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER GENETICS; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CHROMOSOMAL LOCALIZATION; CHROMOSOME ABERRATION; CHROMOSOME STRUCTURE; DNA METHYLATION; GENE LOCATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; REVIEW; TESTIS; TISSUE DISTRIBUTION; X CHROMOSOME;

EID: 0033993651     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevoncog.v11.i1.40     Document Type: Review

References (136)

1. Abraham, M.: The male germ cell protective barrier along phylogenesis. Int. Rev. Cytogen., 130: 111-190 (1991).
2. Akbasak, A. and B. Sunar-Akbasak: Oncogenes: cause or consequence in the development of glial tumors. J. Neurol. Sci., 111:119-133 (1992).
3. Aman, M. J., N. Tayebi, N. I. Obiri, P. K. Puri, W. S. Modi, and W. J. Leonard: cDNA cloning and characterization of the human interleukin-13 receptor α chain. J. Biol. Chem., 271:29265-29270 (1996).
4. Antequera, F. and A. Bird: CpG islands. EXS, 64:169-185 (1993a).
5. Antequera, F. and A. Bird: Number of CpG islands and genes in human and mouse. Proc. Natl. Acad. Sci. U.S.A., 90:11995-11999 (1993).
6. Ayyoub, A., H. Mazarguil, B. Monsarrat, B. Van den Eynde, and J. E. Gairin: A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells. J. Biol. Chem., 274:10227-10234 (1999).
7. Baylin, S. B.: Tying it all together: Epigenetics, genetics, cell cycle, and cancer. Science, 277: 1948-1949 (1997).
8. Baylin, S. B., J. G. Herman, J. R. Graff, P. M. Vertino, and J. P. Issa: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 72:141-196 (1998).
9. Berens, M. E., W. S. McDonough, M. D. Berg, and A. Giese: Genetics of glioma migration and invasion: mRNA differential display analysis reveals diverse biochemical determinants of the invasive behavior. Neuro-Oncology, 1:298 (1999).
10. Bestor, T., A. Laudano, R. Mattaliano, and V. Ingram: Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J. Mol. Biol., 203:971-983 (1988).
11. Bhattacharya, S. K., S. Ramchandani, N. Cervoni, and M. Szyf: A mammalian protein with specific demethylase activity for mCpG DNA. Nature, 397:579-583 (1999).
12. Bird, A.: The essentials of DNA methylation. Cell, 70:5-8 (1992).
13. Bishop, J. M.: Molecular themes in oncogenesis. Cell, 64:235-248 (1991).
14. Boel, P., C. Wildmann, M. L. Sensi, R. Brasseur, J. C. Renauld, P. Coulei, T. Boon, and P. van der Bruggen: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity, 2:167-175 (1995).
15. Boon, T., J. C. Cerottini, B. van den Eynde, P. van der Bruggen, and A. Van Pel: Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12:337-365 (1994).
16. Brinkmann, U., G. Vasmatzis, B. Lee, N. Yerushalmi, M. Essand, and I. Pastan: PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis and uterus. Proc. Natl. Acad. Sci. U.S.A., 95:10757-10762 (1998).
17. Brinkmann, U., G. Vasmatzia, B. Lee, and I. Pastan: Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res., 59:1445-1448 (1999).
18. Caput, D., P. Laurent, M. Kaghad, J-M. Lelias, S. Lefort, N. Vita, and P. Ferrara: Cloning and characterization of a specific interleukin (IL-13) binding protein structurally related to the IL-5 receptor α chain. J. Biol. Chem., 271:16921-16926 (1996).
19. Chen, E., S. H. Lin, L.W. K. Chung, and R. A. Sikes: Isolation and characterization of PAGE-1 and GAGE-7. J. Biol. Chem., 273:17618-17625 (1998a).
20. Chen, R. Z., U. Pettersson, C. Beard, L. Jackson-Grusby, and R. Jaenisch: DNA hypomethylation leads to elevated mutation rates. Nature, 395:89-93 (1998b).
21. Chen, Y. T., A. O. Gure, S. Tsang, E. Stockert, E. Jager, A. Knuth, and L. J. Old: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl. Acad. Sci. U.S.A., 95:6919-6923 (1998c).
22. Chen, Y. T., M. J. Scanlan, U. Sahin, O. Tureci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U.S.A., 94:1914-1918 (1997).
23. Christman, J. K., G. Sheikhnejad, M. Dizik, S. Abeleah, and E. Wainfan: Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe dietary methyl deficiency. Carcinogenesis, 14:551-557 (1993).
24. Coley, W. B.: The treatment of malignant tumors by related inoculations of erysipelas with a report of original cases. Am. J. Med. Sci., 105:487-511 (1893).
25. Collins, V. P.: Progression as exemplified by human astrocytic tumors. Sem. Cancer Biol., 9: 267-276 (1999).
26. Cross, S. H. and A. P. Bird: CpG islands and genes. Curr. Opin. Genet. Dev., 5:309-314 (1995).
27. Cross, S. H., R. R. Meehan, X. Nan, and A. Bird: A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. Nature Genet., 16:256-259 (1997).
28. Davis, F. G., S. Freels, J. Grutsch, S. Barlas, and S. Brem: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J. Neurosurg., 88:1-10 (1998).
29. De Backer, O., K. C. Arden, M. Boreti, V. Vantomme, C. De Smet, S. Czekay, C. S. Viars, E. De Plaen, F. Brasseur, P. Chomez, B. Van den Eynde, T. Boon, and P. van der Bruggen: Characterization of the GAGE genes that are expressed in various human cancers and in normal testes. Cancer Res., 59:3157-3165 (1999).
30. De Smet, C., O. De Backer, I. Faraoni, C. Lurquin, F. Brasseur, and T. Boon: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. U.S.A., 93:7149-7153 (1996).
31. Debinski, W., N. I. Obiri, I. Pastan, and R. K. Puri: A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem., 270:16775-16780 (1995a).
32. Debinski, W., N. I. Obiri, S. K. Powers, I. Pastan, and R. K. Puri: Human glioma cells over-express receptor for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin. Cancer Res., 1:1253-1258 (1995b).
33. Debinski, W., R. Miner, P. Leland, N. I. Obiri, and R. K. Puri: Receptor for IL-13 does not interact with IL-4 but receptor for IL-4 interacts with IL-13 on human glioma cells. J. Biol. Chem., 271:22428-22433 (1996).
34. Debinski, W., D. M. Gibo, N. I. Obiri, A. Kealiher, and R. K. Puri: Novel anti-brain tumor cytotoxins specific for cancer cells. Nature Biotech., 16:449-453 (1998a).
35. Debinski, W.: An immune regulatory cytokine and glioblastoma multiforme: an unexpected link. Crit. Rev. Oncogen., 9: 256-268 (1998b).
36. Debinski, W., D. Gibo, S. W. Hulet, J. R. Connor, and G. Y. Gillespie: Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer Res., 5: 985-990 (1999a).
37. Debinski, W. and J. P. Thompson: Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas. Clin. Cancer Res., 5:3143s-3147s (1999).
38. Debinski, W. and M. Gibo: Gene expression of interleukin 13 binding proteins. Fourth Annual Meeting of the Society for Neuro-Oncology, Scottsdale, AZ, November 19-21 (1999c).
39. Disis, M. L., J. R. Gralow, H. Bernhard, S. L. Hand, W. D. Rubin, and M. A. Cheever: Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J. Immunol, 156: 3151-3158 (1996).
40. Donaldson, D. D., M. J. Whitters, L. J. Fitz, T. Y. Neben, H. Finnerty, S. L. Henderson, R. M. O'Hara Jr., D. R. Beier, K. J. Turner, C. R. Wood, and M. Collins: The murine IL-13 receptor α2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J. Immunol., 161: 2317-2324 (1998).
41. Donnelly, J. J., J. B. Ulmer, J. W. Shiver, and M. A. Liu: DNA vaccines. Annu. Rev. Immunol., 15: 617-648 (1997).
42. El-Deiry, W. S., B. D. Nelkin, P. Celano, R. W. Yen, J. P. Falco, S. R. Hamilton, and S. B. Baylin: High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc. Natl. Acad. Sci. U.S.A., 88: 3470-3474 (1991).
43. Englander, E. W., A. P. Wolffe, and B. H. Howard: Nucleosome interactions with a human Alu element. J. Biol. Chem., 268: 19565-19573 (1993).
44. Feinberg, A. P. and B. Vogelstein: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 301: 89-92 (1983).
45. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, I. De Plaen, B. Lethe, F. Brasseur, and T. Boon: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179: 921-930 (1994).
46. Gnarra, J. R., K. Tory, Y. Weng, L. Schmidt, M. H. Wei, H. Li, F. Latif, S. Liu, F. Chen, F. M. Duh, I. Lobensky, D. R. Duan, C. Florence, R. Pozzatti et al.: Mutations of the VHL tumor suppressor gene in renal carcinoma. Nature Genet., 7: 85-90 (1994).
47. Goto, T. and M. Monk: Regulation of X-chromosome inactivation in development in mice and humans. Microbiol. Mol. Biol. Rev., 62: 362-378 (1998).
48. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878 (1994).
49. Greten, T. F. and E. M. Jaffee: Cancer vaccines. J. Clin. Oncol., 17: 1047-1060 (1999).
50. Guillaudeux, T., E. Gomez, M. Onno, B. Drenou, D. Segretain, S. Alberti, H. Lejeune, R. Fauchet, B. Jegou, and P. Le Bouteiller: Expression of HLA class I genes in meiotic and post-meiotic human spermatogenic cells. Biol. Reprod., 55:99-110 (1996).
51. Guo, J., F. Apiou, M.-P. Mellerin, B. Lebeau, Y. Jacques, and S. Minvielle: Chromosome mapping and expression of the human interleukin-13 receptor. Genomics, 42:141-145 (1997).
52. Hafkemeyer, P., U. Brinkmann, M. M. Gottesman, and I. Pastan: Apoptosis induced by Pseudomonas exotoxin: a sensitive and rapid marker for gene delivery in vivo. Hum. Gene Ther., 10:923-934 (1999).
53. Hanada, M., D. Delia, A. Aiello, E. Stadtmauer, and J. C. Reed: Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphomcytic leukemia. Blood, 82:1820-1828 (1993).
54. Harada, K., T. Nishizaki, S. Ozaki, H. Kubota, H. Ito, and K. Sasaki: Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res., 58:4694-4700 (1998).
55. Herman, J. G., A. Merlo, L. Mao, R. G. Lapidus, J. P. Issa, N. E. Davidson, D. Sidransky, and S. B. Baylin: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55:4525-4530 (1995).
56. Hilton, D. J., J.-G. Zhang, D. Metcalf, W. S. Akexander, N. A. Nicola, and T. A. Wilson: Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. U.S.A., 93:497-501 (1996).
57. Huhn, S. L., G. Mohapatra, A. Bollen, K. Lamborn, M. D. Prados, and B. G. Feurstein: Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiation treatment outcome. Clin. Cancer Res., 5:1435-1443 (1999).
58. Hutter, H. and G. Dohr: HLA expression on immature and mature human germ cells. J. Reprod. Immunol., 38:101-122 (1998).
59. Idzerda, R. L., C. J. March, B. Mosley, S. D. Lyman, T. Vanden Bos, S. D. Gimpel, W. S. Din, K. H. Grabstein, M. B. Widmer, L. S. Park, D. Cosman, and M. P. Beckmann: Human interleukin-4 receptor confers biological responsiveness and defines a novel receptor superfamily. J. Exp. Med., 171:861-873 (1990).
60. Iglewski, B. H. and D. Kabat: NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc. Natl. Acad. Sci. U.S.A., 72:2284-2288 (1975).
61. Itoh, K., A. Hayashi, M. Nakao, T. Hoshino, N. Seki, and S. Shichijo: Human tumor rejection antigens MAGE. J. Biochem., 119:385-390 (1996).
62. Janeway, C. A. and P. Travers: ImmunoBiology: The Immune System in Health and Disease, 3rd edition. Current Biology Limited, 1997.
63. Jung, V., B. F. Romeiko, W. Henn, W. Feiden, J. R. Moringlane, K. D. Zang, and S. Urbschat: Evidence of focal genetic microheterogeneity in glioblastoma mutliforme by area-specific CGH on microdissected tumor cells. J. Neuropathol. Exp. Neurol., 58:993-999 (1999).
64. Kass, S. U., D. Pruss, and A. P. Wolffe: How does DNA methylation repress transcription? Trends Genet., 13:444-449 (1997).
65. Kass, S. U., N. Landsberger, and A. P. Wolffe: DNA methylation directs a time-dependent repression of transcription initiation. Curr. Biol., 7:157-165 (1997)
66. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U.S.A., 91:3515-3519 (1994a).
67. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg: Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U.S.A., 91:6458-6462 (1994b).
68. Keppler-Hafkemeyer, A., U. Brinkmann, and I. Pastan: Role of caspases in immunotoxin-induced apoptosis of cancer. Biochemistry, 37:16934-16942 (1998).
69. Kleihues, P. and H. Ohgaki: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology, 1:44-51 (1999).
70. Knudson, A. G.: Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A., 68:820-823 (1971).
71. Knudson, Jr., A. G., H. W. Hethcote, and B. W. Brown: Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A., 72:5116-5120 (1975).
72. Lei, H., S. P. Oh, M. Okano, R. Juttermann, K. A. Gross, R. Jaenisch, and E. Li: De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development, 122:3195-3205 (1996).
73. Lethe, B., S. Lucas, S. Michaux, C. De Smet, D. Godelaine, A. Serrano, E. DePlaen, and T. Boon: LAGE-1, a new gene with tumor specificity. Int. J. Cancer, 76:903-908 (1998).
74. Li, Q., A. Jedlicka, N. Ahuja, M. C. Gibbons, S. B. Baylin, P. C. Burger, and J. P. Issa: Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene, 16:3197-3202 (1998).
75. Lucas, S., C. De Smet, K. C. Arden, C. S. Viars, B. Lethe, C. Lurquin, and T. Boon: Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res., 58:743-752 (1998).
76. Maeurer, M. J., W. J. Storkus, J. M. Kirkwood, and M. T. Lotze: New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res., 6:11-24 (1996).
77. Magewu, A. N. and P. A. Jones: Ubiquitous and tenacious methylation of the CpG site in codon 248 of p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. Mol. Cell. Biol., 14:4225-4232 (1994).
78. Marahrens, Y.: X-inactivation by chromosomal pairing events. Genes Dev., 13: 2624-2632 (1999).
79. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, J. L. Canon, C. Laurent, J. M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jager, F. Brasseur, J. Herman, P. G. Coulie, and T. Boon: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63: 883-885 (1995).
80. Marshall, C. J.: Tumor suppressor genes. Cell, 64: 313-326 (1991).
81. McKenzie, A. N. J., J. R. Culpepper, R. De Waal Malefyt, F. Briere, J. Punnonen, G. Aversa, A. Sato, W. Dang, B. G. Cocks, S. Menon, J. E. De Vries, J. Banchereau, and G. Zurawski: Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc. Natl. Acad. Sci. U.S.A., 90: 3735-3739 (1993).
82. Miloux, B., P. Laurent, O. Bonnin, J. Lupker, D. Caput, N. Vita, and P. Ferrara: Cloning of the human IL-13Rα of a functional IL-4/IL-13 receptor complex. FEBS Lett., 40: 163-166 (1997).
83. Minty, A., P. Chalon, J. M. Derocq, X. Dumont, J. C. Guillemot, M. Kaghad, C. Labit, P. Leplatois, P. Liauzun, B. Miloux, C. Minty, P. Casellas, G. Loison, J. Lupker, D. Shire, P. Ferrara, and D. Caput: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature, 36: 248-251 (1993).
84. Mise, N., Y. Goto, N. Nakajima, and N. Takagi: Molecular cloning of antisense transcripts of the mouse Xist gene. Biochem. Biophys. Res. Comm., 258: 537-541 (1999).
85. Monk, M.: Methylation and the X chromosome. Bioessays, 4: 204-208 (1986).
86. Murata, T., N. I. Obiri, W. Debinski and R. K. Puri: Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem. Biophys. Res. Comm., 238: 92-94 (1997).
87. Nagane, M., H. J. Huang, and W. K. Cavenee: Advances in the molecular genetics of gliomas. Curr. Opin. Oncol., 9: 215-222 (1997).
88. O'Neill, L. P., A. M. Koehane, J. S. Lavender, V. McCabe, E. Heard, P. Avner, N. Brockdorff, and B. M. Turner: A developmental switch in H4 acetylation upstream of Xist plays a role in X chromosome inactivation. EMBO J., 18: 2897-2907 (1999).
89. Obiri, N. I., P. Leland, T. Murata, W. Debinski, R. K. Puri: The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4. J. Immunol., 158: 756-764 (1997).
90. Ohtani-Fujita, N., T. Fujita, A. Aoike, N. E. Osifchin, P. D. Robbins, and T. Sakai: CpG methylation inactivates the promoter activity of the human retinoblastoma tumor suppressor gene. Oncogene, 8: 1063-1067 (1993).
91. Old, L. J. and T. C. Chen: New paths in human cancer serology. J. Exp. Med., 187: 1163-1167 (1998).
92. Oneill, R. J. W., M. J. Oneill, and J. A. Graves: Undermethylation associated with retroelement activation and chromosome remodeling in an interspecific mammalian hybrid. Nature, 393: 68-72 (1998).
93. Pardoll, D. M.: Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. U.S.A., 96: 5340-5342 (1999).
94. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gplOO modified at HLA-A *0201-binding residues. J. Immunol., 157: 2539-2548 (1996).
95. Pogribny, I. P., L. A. Poirier, and S. J. James: Differential sensitivity to loss of cytosine methyl groups within the hepatic p53 gene of folate/methyl deficient rats. Carcinogenesis, 16: 2863-2867 (1995).
96. Pontecorvo, G., B. De Felice, and M. Carfagna: Variability of DNA methylation pattern in somatic and germ cells in male newt Triturus cristatus carnifex. FEBS Lett., 432: 77-81 (1998).
97. Ramchandani, S., S. K. Bhattacharya, N. Cervoni and M. Szyf: DNA methylation is a reversible biological signal. Proc. Natl. Acad. Sci. U.S.A., 96: 6107-6112 (1999).
98. Rosenberg, S. A. and D. E. White: Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emph. Tumor Immunol., 19: 81-84 (1996).
99. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Yang , C. A. Seip, C. Simpson, C. Carter, S. Bock, D. Schwartzentruber, J. P. Wei, and D. E. White: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, special report. N. Engl. J. Med., 319: 1676-1680 (1988).
100. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. R. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn, and D. E. White: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med., 4: 321-327 (1998).
101. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, and M. Pfreundschuh: Human tumors elicit multiple specific immune response in autologous host. Proc. Natl. Acad. Sci. U.S.A., 92: 11810-11813 (1995).
102. Sahin, U., O. Tureci, Y. T. Chen, G. Seitz, C. Villena-Heinsen, L. J. Old, and M. Pfreundschuh: Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int. J. Cancer, 78: 387-389 (1998).
103. Sakai, T., J. Toguchida, N. Ohtani, D. W. Yandell, J. M. Rappaport, and T. P. Dryja: Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet., 48: 880-888 (1991).
104. Scarcella, D. L., C. W. Chow, M. F. Gonzales, C. Economou, F. Brasseur, and D. M. Ashley: Expression of MAGE and GAGE in high-grade brain tumors: a potential tar-get for specific immunotherapy and diagnostic markers. Clin. Cancer Res., 5: 335-341 (1999).
105. Schrock, E., G. Thiel, T. Lozanova, S. du Manoir, M.-C. Meffert, A. Jauch, M. R. Speicher, P. Nurnberg, S. Vogel, W. Janisch, H. Donis-Keller, T. Ried, R. Witkowski, and T. Cremer: Comparative genomic hybridization of human malignant gliomas reveals multiple amplification sites and nonrandom chromosmal gains and losses. Am. J. Pathol., 144:1203-1218 (1994).
106. Serrano, A., A. Garcia, E. Abril, F. Garrido, and F. Ruiz-Cabello: Methylated CpG points identified within MAGE-1 promoter are involved in gene repression. Int. J. Cancer, 68:464-470 (1996).
107. Shichijo, S., A. Yamada, K. Sagawa, O. Iwamoto, M. Sakata, K. Nagai, and K. Itoh: Induction of Mage genes in lymphoid cells by the demethylating agent 5-aza-2′-deoxycytidine. Jap. J. Cancer Res., 87:751-756 (1996).
108. Siegfried, Z. and H. Cedar: DNA methylation: a molecular lock. Curr. Biol., 7:R305-302 (1997).
109. Simons, J. W., E. M. Jaffee, C. E. Weber, H. I. Levitsky, W. G. Nelson, M. A. Carducci, A. J. Lazenby, L. K. Cohen, C. C. Finn, S. M. Clift, K. M. Hauda, L. A. Beck, K. M. Leiferman, A. H. Owens, Jr., S. Piantadosi, G. Dranoff, R. C. Mulligan, D. M. Pardoll, and F. F. Marshall: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57:1537-1546 (1997).
110. Singal, R. and G. D. Ginder: DNA methylation. Blood, 93:4059-4070 (1999).
111. Streilein, J. W.: Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments. Curr. Opin. Immunol., 5:428-432 (1993).
112. Szyf, M., J. Theberge, and V. Bozovic: Ras induces a general DNA demethylation activity in mouse embryonal P19 cells. J. Biol. Chem., 270:12690-12696 (1995).
113. Strom, T. M., G. Nyakatura, H. Hellebrand, B. Drescher, A. Rosenthal, and A. Meindel, GenBank accession no. AJ005894.
114. Takechi, Y., I. Kara, C. Naftzger, Y. Xu, and A. N. Houghton: A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin. Cancer Res., 2:1837-1842 (1996).
115. Tate, P. H. and A. P. Bird: Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev., 3:226 (1993).
116. Tazi, J. and A. Bird: Alternative chromatin structure at CpG islands. Cell, 60:909-920 (1990).
117. Thompson, J. P. and W. Debinski: Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors. J. Biol. Chem., 274:29944-29950 (1999).
118. Trasler, J. M.: Origins and roles of genomic methylation patterns in male germ cells. Sem. Cell. Dev. Biol., 9:379-391 (1998).
119. Traversari, C., P. van der Bruggen, B. Van den Eynde, P. Hainaut, C. Lemoine, N. Ohta, L. J. Old, and T. Boon: Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics, 35:145-152 (1992a).
120. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon: A nonapepide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T-lymphocytes directed against tumour antigen MZ2-E. J. Exp. Med., 176:1453-1458 (1992b).
121. Tureci, O., U. Sahin, C. Zwick, F. Neumann, and M. Pfreundschuh: Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. Hybridoma, 18:23-28 (1999).
122. Tureci, O., U. Sahin, C. Zwick, M. Koslowski, G. Seitz, and M. Pfreundschuh: Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Natl. Acad. Sci. U.S.A., 95:5211-5216 (1998b).
123. Tureci, O., Y. T. Chen, U. Sahin, A. O. Gure, C. Zwick, C. Villena, S. Tsang, G. Seitz, L. J. Old, and M. Pfreundschuh: Expression of SSX genes in human tumors. Int. J. Cancer, 77:19-23 (1998a).
124. Uchida, T., T. Kinoshita, H. Nagai, Y. Nakahara, H. Saito, T. Hotto, and T. Murate: Hypermthylation of the p15INK4B gene in myelodysplastic syndrome. Blood, 90:1403-1409 (1997).
125. Van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254:1643-1647 (1991).
126. Van der Bruggen, P., J. P. Szikora, P. Boel, C. Wildmann, M. Somville, M. Sensi, and T. Boon: Autologous cytolytic T-lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 1601. Eur. J. Immunol., 24:2134-2140 (1994).
127. Vertino, P. M., R. W. Yen, J. Gao, and S. B. Baylin: De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol. Cell. Biol., 16:4555-4565 (1996).
128. Weber, R. G., M. Sabel, J. Reifenberger, C. Sommer, J. Oberstrass, G. Reinferberger, M. Kiessling, and T. Cremer: Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene, 5:983-994 (1996).
129. Weissbach, A.: A chronicle of DNA methylation (1948-1975). EXS, 64:1-10 (1993).
130. Wingo, P. A., S. Landis, S. Parker et al.: Using cancer registry and vital statistics data to estimate the number of new cases and deaths in the United States for the upcoming year. J. Reg. Manage., 25:43-51 (1998).
131. Wu, J., J. G. Herman, G. Wilson, R. Y. Lee, R. W. Yen, M. Mabry, A. de Bustros, B. D. Nelkin, and S. B. Baylin: Expression of prokaryotic HhaI DNA methyltransferase is transforming and lethal to NIH 3T3 cells. Cancer Res., 56:616-622 (1996).
132. Yen, R. W., P. M. Vertino, B. D. Nelkin, J. J. Yu, W. el-Deiry, A. Cumaraswamy, G. G. Lennon, B. J. Trask, P. Celano, and S. B. Baylin: Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res., 20:2287-2291 (1992).
133. Yoder, J. A. and T. H. Bestor: A candidate mammalian DNA methyltransferase related to pmt1p of fission yeast. Hum. Mol. Genet., 7:279-284 (1998).
134. Zou, J.-P., L. A. Morford, C. Chougnet, A. R. Dix, A. G. Brooks, N. Torres, J. D. Shuman, J. E. Coligan, W. H. Brooks, T. L. Roszman, and G. M. Shearer: Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J. Immunol., 162:4882-4892 (1999).
135. Zurawski, S. M., F. Vega Jr., B. Huyghe, and G. Zurawski: Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J., 12:2663-2670 (1993).
136. Zurawski, G. and J. E. de Vries: Interleukin 13 elicits a subset of the activities of its close relative interleukin 4. Stem Cells, 12:169-174 (1994).